Related Experiment Video
Updated: Jun 13, 2026
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Advanced Concepts and Controversies in the Recognition and Management of Patent Ductus Arteriosus in Premature
Aisling Smith1, Danielle R Rios2, Patrick J McNamara3
1Department of Neonatology, The Rotunda Hospital, Dublin D01 P5W9, Ireland.
Insights
The patent ductus arteriosus (PDA) in neonates is complex. Current treatments may close the duct but haven't proven to reduce related complications, necessitating further research.
Area of Science:
- Neonatology
- Pediatric Cardiology
Background:
- The patent ductus arteriosus (PDA) is a persistent topic of debate in neonatology.
- Management practices for PDA exhibit significant heterogeneity despite extensive research.
- Pharmacologic therapies increase ductal closure rates but lack definitive evidence of reducing PDA-related morbidities in randomized controlled trials.
Purpose of the Study:
- To discuss advanced concepts and controversies in PDA recognition and management.
- To highlight nuances often overlooked in PDA trial interpretations.
- To explore factors hindering the establishment of a causal link between ductal patency and neonatal morbidity.
Main Methods:
- Review of existing literature on PDA management and clinical trials.
- Analysis of controversies and challenges in PDA research.
- Discussion of potential future research directions.
Main Results:
- Significant heterogeneity exists in PDA management strategies.
- No randomized controlled trial has conclusively demonstrated reduced PDA-related morbidities with current pharmacologic therapies.
- Previous research has faced challenges in establishing a direct causal link between ductal patency and neonatal morbidity.
Conclusions:
- Advanced concepts and controversies in PDA management require further exploration.
- Nuances in PDA trial interpretation are critical for understanding treatment efficacy.
- Future studies should focus on targeted ductal closure to investigate potential benefits for neonatal outcomes.
Abstract:
The patent ductus arteriosus (PDA) remains one of the most debated topics within neonatology. Despite thousands of studies, there is significant heterogeneity in management practices. Although pharmacologic therapy results in increased ductal closure, no randomized controlled trial has definitively reported reduced PDA-related morbidities. We will discuss advanced concepts and controversies in the recognition and management of the PDA and highlight nuance frequently missing from interpretations of PDA-focused trials, explore issues which have precluded previous research from establishing a causal link between ductal patency and neonatal morbidity, and suggest directions for future studies investigating the potential merits of targeted ductal closure.
